Emily Field, Barclays head of European pharmaceutical research, joins CNBC's 'The Exchange' to discuss why Novo Nordisk ...

Stocks traded sharply higher Friday as a key inflation measure came in lower than expected. The Dow Jones Industrial Average ...

Novo Nordisk faces scrutiny after disappointing trial results for CagriSema, a next-gen obesity drug, caused a significant market valuation drop. Analysts question whether side effects limited dosage ...

US stocks rallied on Friday to more than halve their losses in what had been one of their worst weeks of the year.

Las acciones de la farmaceútuca danesa Novo Nordisk A/S registraron la mayor caída de su historia tras informar resultados ...

Novo Nordisk ( NVO) reported its newest GLP-1 product, CagriSema, provides an average of 22.7% weight loss, but that wasn't ...

After a stunning 703% run-up in price over the past five years, shares of Eli Lilly and Co. have been on a roller-coaster ...

Although Novo underscored that patients in the trial achieved up to 22.7% of weight loss with CagriSema, analysts previously said they were hoping to see whether it would significantly beat Lilly’s ...

Novo Nordisk reported disappointing results from its trial on the obesity drug CagriSema, causing a significant drop in market value. The drug's weight-loss outcome was below expectations, affecting ...

Volkswagen has reached a deal with the IG Metall union that will avoid closing German plants in exchange for capacity ...

Stocks were sharply higher in early-afternoon trading Friday, reversing earlier losses, as the market reacted to tame ...

New clinical trial data from Novo Nordisk raise questions for the broad landscape of obesity drug development and the way ...